ArticleCornea2010
Nona-D-arginine amide suppresses corneal cytokines in Pseudomonas aeruginosa keratitis.
Article in Cornea, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Cationic Arginine-Rich Peptides (CARPs): A Novel Class of Neuroprotective Agents With a Multimodal Mechanism of Action.Frontiers in neurology · 2020Pooled it
- Peptide therapeutics for treating ocular surface infections.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2014Review
- In vitro model suggests oxidative stress involved in keratoconus disease.Scientific reports · 2014Article
- Animal models of bacterial keratitis.Journal of biomedicine & biotechnology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
purposeNona-D-arginine (D9R) amide suppressed interleukin 1β production during Pseudomonas aeruginosa corneal infection. The purpose of this study was to determine the cellular disposition of D9R and its effect on other inflammatory mediators induced by infection.
methodsMouse eyes received 5 μL of either phosphate-buffered saline (PBS, pH 7.4) or 100-μM D9R hourly for 5 hours (total of 6 drops per eye) immediately after corneal wounding and infection with 1 × 10 colony-forming units (CFUs) of P. aeruginosa strain PAO1. At 6, 12, and 24 hours postinfection, eyes were scored on a scale of 0 (normal eye) to +4 (corneal perforation). After scoring, mice were killed and eyes enucleated. Whole eyes were used for determining viable CFUs per eye. Corneas were excised for quantitation of tumor necrosis factor α, interferon γ, interleukin 10, and granulocyte-macrophage colony-stimulating factor. The fate of D9R in cells was determined using a labeled peptide.
resultsEyes treated with D9R had significantly lower disease scores (P ≤ 0.001) and fewer CFUs (P ≤ 0.01) than those in PBS-treated eyes. No corneal cytokines were detected in any D9R-treated eyes. In contrast, beginning at 12 hours postinfection, increasing amounts of tumor necrosis factor alpha, interleukin 10, and granulocyte-macrophage colony-stimulating factor were detectible in corneas of PBS-treated eyes. Within 60 minutes, D9R accumulated in the cell nucleus and nucleolus and remained for over 24 hours.
conclusionD9R reduces the severity of P. aeruginosa ocular infection in part by reducing bacterial burden and in part by controlling a destructive proinflammatory response. D9R might be a useful alternative to steroids in treating other inflammation-mediated pathologies of the eye.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.